Business
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announced it will donate SofPulse® devices to Intensive Care Units and medical professionals for investigational use to evaluate SofPulse® PEMF technology’s inflammation reduction effect to determine potential efficacy in reducing symptoms of respiratory inflammation and distress in COVID-19 patients. As of March 15th, 2020, over 160,000 worldwide cases of COVID-19 have been reported and the World Health Organization (“WHO”) has labeled the spread of this virus a pandemic. Medical researchers who have previously successfully studied SofPulse® in trials and clinical studies for reduction of pain and edema postoperatively, as well as for (TBI) Traumatic Brain Injury have identified an anti-inflammatory response through which SofPulse® technology may help to mitigate the severe respiratory inflammation observed in some COVID-19 patients. A recent publication in the Journal of Biological Regulators and Homeostatic Agents proposes the role of inflammation in coronavirus infection(https://www.ncbi.nlm.nih.gov/pubmed/32013309/). Endonovo Chief Medical Officer, Dr. Nev Zubcevik states, “COVID-19 has been shown to be causing a release of pro-inflammatory cytokines which contribute to overwhelming inflammation termed a \"cytokine storm\" in the respiratory system leading to worsened clinical outcomes. The SofPulse® Pulsed Electromagnetic Field device is FDA-cleared for post-operative management of pain and edema where clinical analysis has shown that the primary mechanism of action is noninvasive reduction of pro-inflammatory cytokine Interleukin 1 Beta and improvement of circulation in tissues. In clinical studies, SofPulse® PEMF technology is proven to reduce IL-1 beta by 275% at the 18-hour mark after surgery. This is the same interleukin response that has been implicated in the heightened inflammatory response resulting from the COVID-19 infection leading to increases in morbidity and mortality rates.” Dr. Zubcevik further states, “Although there is no clinical trial or test proving the efficacy of SofPulse® in treating respiratory inflammatory conditions, we have observed success in clinical trials using SofPulse® ...